AustralieFrV1, PubMed, Checkpoint, bibRecord, 002738

Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.

Identifieur interne : 002738 ( PubMed/Checkpoint ); précédent : 002737; suivant : 002739

Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.

Auteurs : Merlin C. Thomas [Australie] ; Mark Woodward [Australie] ; Bruce Neal [Australie] ; Qiang Li [Australie] ; Raelene Pickering [Australie] ; Michel Marre [France] ; Bryan Williams [Royaume-Uni] ; Vlado Perkovic [Australie] ; Mark E. Cooper [Australie] ; Sophia Zoungas [Australie] ; John Chalmers [Australie] ; Graham S. Hillis [Australie]

Source :

Diabetes care [ 1935-5548 ] ; 2015.

RBID : pubmed:26253728

Descripteurs français

English descriptors

KwdEn :
- Advanced Glycosylation End Product-Specific Receptor (metabolism), Aged, Biomarkers (metabolism), Diabetes Mellitus, Type 2 (metabolism), Diabetes Mellitus, Type 2 (prevention & control), Diabetic Angiopathies (metabolism), Diabetic Angiopathies (prevention & control), Diabetic Nephropathies (metabolism), Diabetic Nephropathies (prevention & control), Double-Blind Method, Drug Therapy, Combination, Epidemiologic Methods, Female, Glycosylation End Products, Advanced (metabolism), Humans, Hypoglycemic Agents (administration & dosage), Male, Receptors, Immunologic, Treatment Outcome.
MESH :
- chemical , administration & dosage : Hypoglycemic Agents.
- chemical , metabolism : Advanced Glycosylation End Product-Specific Receptor, Biomarkers, Glycosylation End Products, Advanced.
- metabolism : Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Nephropathies.
- prevention & control : Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Nephropathies.
- Aged, Double-Blind Method, Drug Therapy, Combination, Epidemiologic Methods, Female, Humans, Male, Receptors, Immunologic, Treatment Outcome.

Abstract

This study explored whether activation of the receptor for advanced glycation end products (RAGE) is implicated in the development of diabetes complications.

DOI: 10.2337/dc15-0925
PubMed: 26253728

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002906
to stream PubMed, to step Curation: 002837

Links to Exploration step

pubmed:26253728

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.</title>
<author><name sortKey="Thomas, Merlin C" sort="Thomas, Merlin C" uniqKey="Thomas M" first="Merlin C" last="Thomas">Merlin C. Thomas</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, U.K. Department of Epidemiology, Johns Hopkins University, Baltimore, MD markw@georgeinstitute.org.au.</nlm:affiliation>
<country wicri:rule="url">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, U.K. Department of Epidemiology, Johns Hopkins University, Baltimore</wicri:regionArea>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
<settlement type="city">Sydney</settlement>
</placeName>
<orgName type="university">Université de Sydney</orgName>
</affiliation>
</author>
<author><name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Qiang" sort="Li, Qiang" uniqKey="Li Q" first="Qiang" last="Li">Qiang Li</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pickering, Raelene" sort="Pickering, Raelene" uniqKey="Pickering R" first="Raelene" last="Pickering">Raelene Pickering</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, Bryan" sort="Williams, Bryan" uniqKey="Williams B" first="Bryan" last="Williams">Bryan Williams</name>
<affiliation wicri:level="3"><nlm:affiliation>University College London and the National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, U.K.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University College London and the National Institute for Health Research University College London Hospitals Biomedical Research Centre, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perkovic, Vlado" sort="Perkovic, Vlado" uniqKey="Perkovic V" first="Vlado" last="Perkovic">Vlado Perkovic</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, Mark E" sort="Cooper, Mark E" uniqKey="Cooper M" first="Mark E" last="Cooper">Mark E. Cooper</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zoungas, Sophia" sort="Zoungas, Sophia" uniqKey="Zoungas S" first="Sophia" last="Zoungas">Sophia Zoungas</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hillis, Graham S" sort="Hillis, Graham S" uniqKey="Hillis G" first="Graham S" last="Hillis">Graham S. Hillis</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia Department of Cardiology, Royal Perth Hospital, Perth, Western Australia</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26253728</idno>
<idno type="pmid">26253728</idno>
<idno type="doi">10.2337/dc15-0925</idno>
<idno type="wicri:Area/PubMed/Corpus">002906</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002906</idno>
<idno type="wicri:Area/PubMed/Curation">002837</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002837</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002837</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002837</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.</title>
<author><name sortKey="Thomas, Merlin C" sort="Thomas, Merlin C" uniqKey="Thomas M" first="Merlin C" last="Thomas">Merlin C. Thomas</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, U.K. Department of Epidemiology, Johns Hopkins University, Baltimore, MD markw@georgeinstitute.org.au.</nlm:affiliation>
<country wicri:rule="url">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, U.K. Department of Epidemiology, Johns Hopkins University, Baltimore</wicri:regionArea>
<placeName><settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
<settlement type="city">Sydney</settlement>
</placeName>
<orgName type="university">Université de Sydney</orgName>
</affiliation>
</author>
<author><name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Li, Qiang" sort="Li, Qiang" uniqKey="Li Q" first="Qiang" last="Li">Qiang Li</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pickering, Raelene" sort="Pickering, Raelene" uniqKey="Pickering R" first="Raelene" last="Pickering">Raelene Pickering</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name>
<affiliation wicri:level="3"><nlm:affiliation>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Williams, Bryan" sort="Williams, Bryan" uniqKey="Williams B" first="Bryan" last="Williams">Bryan Williams</name>
<affiliation wicri:level="3"><nlm:affiliation>University College London and the National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, U.K.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University College London and the National Institute for Health Research University College London Hospitals Biomedical Research Centre, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Perkovic, Vlado" sort="Perkovic, Vlado" uniqKey="Perkovic V" first="Vlado" last="Perkovic">Vlado Perkovic</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, Mark E" sort="Cooper, Mark E" uniqKey="Cooper M" first="Mark E" last="Cooper">Mark E. Cooper</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zoungas, Sophia" sort="Zoungas, Sophia" uniqKey="Zoungas S" first="Sophia" last="Zoungas">Sophia Zoungas</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hillis, Graham S" sort="Hillis, Graham S" uniqKey="Hillis G" first="Graham S" last="Hillis">Graham S. Hillis</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia Department of Cardiology, Royal Perth Hospital, Perth, Western Australia</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Diabetes care</title>
<idno type="eISSN">1935-5548</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced Glycosylation End Product-Specific Receptor (metabolism)</term>
<term>Aged</term>
<term>Biomarkers (metabolism)</term>
<term>Diabetes Mellitus, Type 2 (metabolism)</term>
<term>Diabetes Mellitus, Type 2 (prevention & control)</term>
<term>Diabetic Angiopathies (metabolism)</term>
<term>Diabetic Angiopathies (prevention & control)</term>
<term>Diabetic Nephropathies (metabolism)</term>
<term>Diabetic Nephropathies (prevention & control)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Epidemiologic Methods</term>
<term>Female</term>
<term>Glycosylation End Products, Advanced (metabolism)</term>
<term>Humans</term>
<term>Hypoglycemic Agents (administration & dosage)</term>
<term>Male</term>
<term>Receptors, Immunologic</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Angiopathies diabétiques ()</term>
<term>Angiopathies diabétiques (métabolisme)</term>
<term>Association de médicaments</term>
<term>Diabète de type 2 ()</term>
<term>Diabète de type 2 (métabolisme)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hypoglycémiants (administration et posologie)</term>
<term>Marqueurs biologiques (métabolisme)</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Méthodes épidémiologiques</term>
<term>Néphropathies diabétiques ()</term>
<term>Néphropathies diabétiques (métabolisme)</term>
<term>Produits terminaux de glycation avancée (métabolisme)</term>
<term>Récepteur spécifique des produits finaux de glycosylation avancée (métabolisme)</term>
<term>Récepteurs immunologiques</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Hypoglycemic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Advanced Glycosylation End Product-Specific Receptor</term>
<term>Biomarkers</term>
<term>Glycosylation End Products, Advanced</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Hypoglycémiants</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
<term>Diabetic Angiopathies</term>
<term>Diabetic Nephropathies</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Angiopathies diabétiques</term>
<term>Diabète de type 2</term>
<term>Marqueurs biologiques</term>
<term>Néphropathies diabétiques</term>
<term>Produits terminaux de glycation avancée</term>
<term>Récepteur spécifique des produits finaux de glycosylation avancée</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
<term>Diabetic Angiopathies</term>
<term>Diabetic Nephropathies</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Epidemiologic Methods</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Receptors, Immunologic</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Angiopathies diabétiques</term>
<term>Association de médicaments</term>
<term>Diabète de type 2</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Méthodes épidémiologiques</term>
<term>Néphropathies diabétiques</term>
<term>Récepteurs immunologiques</term>
<term>Résultat thérapeutique</term>
<term>Sujet âgé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This study explored whether activation of the receptor for advanced glycation end products (RAGE) is implicated in the development of diabetes complications.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26253728</PMID>
<DateCreated><Year>2015</Year>
<Month>09</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>04</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-5548</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>38</Volume>
<Issue>10</Issue>
<PubDate><Year>2015</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Diabetes care</Title>
<ISOAbbreviation>Diabetes Care</ISOAbbreviation>
</Journal>
<ArticleTitle>Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.</ArticleTitle>
<Pagination><MedlinePgn>1891-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2337/dc15-0925</ELocationID>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study explored whether activation of the receptor for advanced glycation end products (RAGE) is implicated in the development of diabetes complications.</AbstractText>
<AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">A case-cohort study was performed in 3,763 participants with prevalent diabetes in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. The hazard ratios (HRs) for death, major cardiovascular events, and new or worsening nephropathy were derived using Cox regression models, and the ability of sRAGE and AGE levels to reclassify the risk of nephropathy was assessed.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjustment for a range of possible confounders and other risk factors, sRAGE levels were associated with all-cause mortality (HR 1.11 for a 1-SD increase of log sRAGE [95% CI 1.00-1.22]; P = 0.045) and new or worsening nephropathy (HR 1.20 for a 1-SD increase of log sRAGE [95% CI 1.02-1.41]; P = 0.032). Circulating AGE levels were also independently associated with new or worsening nephropathy (HR 1.21 for a 1-SD increase [95% CI 1.08-1.36]; P = 0.001). Both markers also significantly improved the accuracy with which the 5-year risk of new or worsening nephropathy could be predicted (net reclassification index in continuous model, 0.25 for sRAGE and 0.24 for AGE levels).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In adults with type 2 diabetes, increased levels of sRAGE are independently associated with new or worsening kidney disease and mortality over the next 5 years. Higher levels of AGE are also associated with an increased risk of adverse renal outcomes. The AGE/RAGE axis may be of importance in the prevention and management of diabetes complications.</AbstractText>
<CopyrightInformation>© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomas</LastName>
<ForeName>Merlin C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Woodward</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia The George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, U.K. Department of Epidemiology, Johns Hopkins University, Baltimore, MD markw@georgeinstitute.org.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Neal</LastName>
<ForeName>Bruce</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Qiang</ForeName>
<Initials>Q</Initials>
<AffiliationInfo><Affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pickering</LastName>
<ForeName>Raelene</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Marre</LastName>
<ForeName>Michel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Hôpital Bichat-Claude Bernard and Université Paris 7, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Williams</LastName>
<ForeName>Bryan</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>University College London and the National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, U.K.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perkovic</LastName>
<ForeName>Vlado</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cooper</LastName>
<ForeName>Mark E</ForeName>
<Initials>ME</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zoungas</LastName>
<ForeName>Sophia</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chalmers</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hillis</LastName>
<ForeName>Graham S</ForeName>
<Initials>GS</Initials>
<AffiliationInfo><Affiliation>The George Institute for Global Health, The University of Sydney, Sydney, New South Wales, Australia Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>ADVANCE Collaborative Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00145925</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>08</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Diabetes Care</MedlineTA>
<NlmUniqueID>7805975</NlmUniqueID>
<ISSNLinking>0149-5992</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000067759">Advanced Glycosylation End Product-Specific Receptor</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017127">Glycosylation End Products, Advanced</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000067759" MajorTopicYN="N">Advanced Glycosylation End Product-Specific Receptor</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003925" MajorTopicYN="N">Diabetic Angiopathies</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003928" MajorTopicYN="N">Diabetic Nephropathies</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017127" MajorTopicYN="N">Glycosylation End Products, Advanced</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>04</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>07</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>8</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>8</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26253728</ArticleId>
<ArticleId IdType="pii">dc15-0925</ArticleId>
<ArticleId IdType="doi">10.2337/dc15-0925</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Maryland</li>
<li>Nouvelle-Galles du Sud</li>
<li>Île-de-France</li>
</region>
<settlement><li>Baltimore</li>
<li>Londres</li>
<li>Paris</li>
<li>Sydney</li>
</settlement>
<orgName><li>Université de Sydney</li>
</orgName>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Thomas, Merlin C" sort="Thomas, Merlin C" uniqKey="Thomas M" first="Merlin C" last="Thomas">Merlin C. Thomas</name>
</noRegion>
<name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name>
<name sortKey="Cooper, Mark E" sort="Cooper, Mark E" uniqKey="Cooper M" first="Mark E" last="Cooper">Mark E. Cooper</name>
<name sortKey="Hillis, Graham S" sort="Hillis, Graham S" uniqKey="Hillis G" first="Graham S" last="Hillis">Graham S. Hillis</name>
<name sortKey="Li, Qiang" sort="Li, Qiang" uniqKey="Li Q" first="Qiang" last="Li">Qiang Li</name>
<name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name>
<name sortKey="Perkovic, Vlado" sort="Perkovic, Vlado" uniqKey="Perkovic V" first="Vlado" last="Perkovic">Vlado Perkovic</name>
<name sortKey="Pickering, Raelene" sort="Pickering, Raelene" uniqKey="Pickering R" first="Raelene" last="Pickering">Raelene Pickering</name>
<name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name>
<name sortKey="Zoungas, Sophia" sort="Zoungas, Sophia" uniqKey="Zoungas S" first="Sophia" last="Zoungas">Sophia Zoungas</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Marre, Michel" sort="Marre, Michel" uniqKey="Marre M" first="Michel" last="Marre">Michel Marre</name>
</region>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Williams, Bryan" sort="Williams, Bryan" uniqKey="Williams B" first="Bryan" last="Williams">Bryan Williams</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002738 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002738 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:26253728
   |texte=   Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:26253728" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.

Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki